Aim: In order to know the present status of drug-induced liver injury (DILI) in Japan, we present the data of prospectively collected DILI cases between 2010 and 2018 from 27 hospitals.
Results: In total, data of 307 cases (125 male and 182 female individuals) aged between 17 and 86 years old were collected. The types of liver injury were as follows: 64% hepatocellular type, 20% mixed type, and 16% cholestatic type. A drug-induced lymphocyte stimulation test was carried out in 59% of cases, and was positive in 48% and semipositive in 3% of cases. Eosinophilia ≥6% was observed in 27% of cases. Fifty-three percent of DILI cases occurred within 30 days and 79% of DILI cases occurred within 90 days after starting drug administration. By the diagnostic scale of the Digestive Disease Week (DDW)-Japan 2004 workshop, 93.8% of cases were diagnosed as "highly probable", and 5.9% as "possible".
Conclusions: Japanese DILI patients are somewhat different from those of Europe and North America. The diagnostic scale of the DDW-Japan 2004 workshop has been used in Japan. However, there are many issues to improve the causality assessment of DILI that we must investigate in the future. It is critical to elucidate the mechanisms of drug metabolism and the pathophysiology of liver injury by various drugs to prevent DILI. is an important cause of acute liver injury and the incidence of DILI seems to be increasing with the increase in the numbers of new drugs.
We previously reported a retrospective analysis of 1676 Japanese DILI cases between 1997 and 2006. 1 In this survey, hepatocellular, mixed, and cholestatic types of liver injury were 59%, 20%, and 21%, respectively. Ursodeoxycholic acid, corticosteroids, and i.v. glycyrrhizin (Stronger Neo-Minophagen C, Minophagen Pharmaceutical Co. Ltd., Tokyo, Japan) were used in 25%, 13%, and 37% of the cases, respectively, and 3.2% of the cases were subjected to plasma exchange. Whereas 87% of cases were cured, 2.4% died and 0.4% of the cases were subjected to liver transplantation. We also postulated a diagnostic scale developed by the Digestive Disease Week (DDW)-Japan 2004 workshop, 2,3 which was a modification of the Roussel Uclaf Causality Assessment Method (RUCAM) scale. 4 In order to know the present status of DILI in Japan, we are now presenting the data of prospectively collected DILI cases between 2010 and 2018 from 27 hospitals. 
METHODS

Case collection
Collected data
The following data for each case were collected: age, sex, basal diseases, type of DILI assessed by R values, 4 causal drugs and their classification, days until onset, druginduced lymphocyte stimulation test (DLST), 5, 6 white blood cell count, percentage of eosinophils, aspartate aminotransferase, ALT, ALP, γ-glutamyltransferase, total bilirubin, markers for hepatitis A, B, and C viruses, antinuclear, antimitochondrial, and anti-M2 antibodies, existence of biliary diseases, shock liver, fever, skin eruption, alcohol intake, drug treatments, outcome, DDW-J 2004 score, 2, 3 and RUCAM score. 4 The protocol of the present study was approved by each institutional ethical committee.
RESULTS
General information of DILI cases
I N TOTAL, 307 cases (125 male and 182 female individuals) aged between 17 and 86 years (average, 58 years; median, 61 years) ( Fig. 1) were collected. The types of liver injury were 64% hepatocellular type, 20% mixed type, and 16% cholestatic type. The characteristics of different types of liver injury are listed in Table 1 . As defined, ALT and ALP levels were the highest in hepatocellular and cholestatic types, respectively, whereas total bilirubin levels were similar among the three types of DILI. Drug-induced lymphocyte stimulation test was undertaken in 59% of cases, and was positive in 48% and semipositive in 3% of cases. Eosinophilia ≥6% was observed in 27% of cases. There were 133 cases (43%) with ALT ≥500 U/L, 62 cases (20%) with ALT ≥1000 U/L, and 24 cases (8%) with total bilirubin ≥10 mg/dL. Figure 2 shows the duration from the start of medication until the onset of liver injury; 53% of DILI cases occurred within 30 days and 79% of DILI cases occurred within 90 days after starting drug treatment. Figure 3 shows the distribution of scores of the diagnostic scale of the DDW-Japan 2004 workshop: 2,3 0.8% were diagnosed as "highly probable" and 5.9% as "possible". The RUCAM score 4 was described in 270 cases; among them, 131 cases (49%) were highly probable, 107 cases (40%) were probable, 29 cases (11%) were possible, and 3 cases (1%) were unlikely.
Duration of treatment until onset of DILI
DDW-Japan 2004 workshop score and RUCUM score
Causal drugs
Percentages of causal drugs, with some overlapping, are shown in Table 2 . Anti-inflammatory drugs, antimicrobial drugs, anticancer drugs, dietary supplements, and drugs for the gastrointestinal system were the top five types of causal drugs. Values are mean ± standard deviation, unless otherwise indicated. ALP, alkaline phosphatase; ALT, alanine aminotransferase. drug
Drug-induced liver injury by dietary supplements
In 34 DILI cases by dietary supplements, the age distribution was similar to other cases (median, 61 years; range, 26-84 years old), and the type of liver injury was also similar (65% hepatocellular, 20% mixed, and 15% cholestatic type). However, the duration until the onset of liver injury with cases by dietary supplements was longer than other DILI cases; 22% occurred within 30 days and 48% occurred within 90 days after starting the drug.
Drug-induced liver injury by Chinese herbal medicines
In the 27 DILI cases by Chinese herbal medicines, although the age distribution was similar to other cases (median, 59 years; range, 30-79 years), the type of liver injury was predominantly hepatocellular (81% hepatocellular, 11% mixed, and 7% cholestatic type). The duration until the onset of liver injury in cases caused by Chinese herbal medicines was similar to other drugs; 58% occurred within 30 days and 77% occurred within 90 days after starting the drug.
Symptoms and treatments
Fever and skin eruption were observed in 54 cases (18%) and 41 cases (13%), respectively. The causal drugs were discontinued in all cases, and the following therapies were carried out: ursodeoxycholic acid in 85 cases (28%), Stronger Neo-Minophagen C in 80 cases (26%), corticosteroid in 33 cases (11%), and anti-allergic drugs in 3 cases (1%).
Outcomes of patients
Plasma exchange was undertaken in 2 cases (1%). There was no case subjected to liver transplantation. All cases except for one, who died with subacute bacterial peritonitis complicated with liver cirrhosis and liver failure, recovered from liver injury. 
DISCUSSION
In the present study, the percentage of female DILI patients (59%) was similar to that of American patients (59%) 7 and Icelandic patients (56%), 8 and was higher than that of Spanish patients (48%). 9 The average and median ages of Japanese DILI patients (58 and 61 years, respectively) were higher than the average age of American patients (49 years), 7 the median age of Icelandic patients (55 years), 8 and the average age of Spanish patients (54 years). 9 This might be due to the longer average lifespan of the Japanese population and multiple medications for elderly Japanese patients.
The percentage of hepatocellular type of injury in the present study was 64%, which was higher than reported in previous surveys in Japan: 46% in the study of Tameda et al. with 2561 cases, undertaken in 1999, 10 and 59% in our study with 1676 cases, undertaken in 2008. 1 This could be due to the decreased prescription of drugs to cause cholestatic DILI such as tiopronin 11 and ticlopidine 12 in Japan. The percentage of hepatocellular type was also higher than in foreign countries: the percentages of hepatocellular/mixed/cholestatic type were 54%/23%/23% in the USA, 7 42%/26%/32% in Iceland, 8 and 55%/21%/25% in Spain. 9 Comparing the results of the present survey with those of the previous survey of Japanese DILI cases between 1997 and 2006, 1 the average age became slightly higher (58 vs. 55 years old), the percentage of hepatocellular type became higher, as discussed above, the percentage of drug treatment for more than 90 days until the onset became higher (21% vs. 16%) and the percentage of cases with positive DLST became higher (48% vs 36%), whereas the percentages of cases with eosinophilia were similar (27% vs. 26%).
In terms of the sensitivity of diagnosis, the diagnostic scale of the DDW-Japan 2004 workshop 1 was higher than the RUCUM scale, 4 suggesting the usefulness of this diagnostic scale. Indeed, the distribution of the RUCUM score was similar to our previous report with 287 Japanese DILI cases. 13 In the present study, the percentage of DILI cases by antimicrobial drugs was lower than that in North America and Europe. [7] [8] [9] This could be due to the reduced incidence of referral of such cases to hepatologists in Japan, because it has been well recognized by Japanese doctors that antimicrobial drugs often cause DILI.
In the reports from North America and Europe, DILI due to Chinese herbal medicines and dietary supplements have been handled together. 14, 15 The situation of Chinese herbal medicines is very specific in Japan. More than 100
Chinese herbal medicines, 2-3 g of freeze-dried granules of herbal extracts, have been approved by the Ministry of Health, Labour and Welfare of Japan, and are widely used in Japan. Therefore, DILI cases due to dietary supplements and Chinese herbal medicines are collected separately in Japan.
The reason for the longer duration until DILI onset due to dietary supplements, which is the same as reported previously, 1 is entirely unknown. Chinese herbal medicines and dietary supplements seem to be major causes of DILI in Asian countries. 16, 17 Indeed, 81% of DILI cases were reported to be caused by complementary and alternative medicines in a report from Singapore, 17 and 42% of DILI cases by herbs and plant products in a report from Korea. 16 The incidence of DILI caused by dietary supplements and Chinese herbal medicines in the present survey was markedly increased compared to the survey by Tameda et al. for the cases between 1989 and 1998 (0.7% by dietary supplements and 4.7% by Chinese herbal medicines). 10 In Japan, the association of special HLA genotypes had been reported to relate to tiopronin-and ticlopidineinduced DILI. 10, 11 Recently, the worldwide results of polymorphism in HLA and other genes in a genome-wide study of DILI cases were published. 18 Furthermore, Kakisaka et al. reported possible serum markers for direct acting antivirals-induced DILI. 19 However, these results are just a starting point to understand the pathogenesis of DILI and to prevent DILI.
In conclusion, Japanese DILI patients have somewhat different characteristics from those of Europe and North America. The diagnostic scale of the DDW-Japan 2004 workshop has been used in Japan. However, there are many issues to improve causality assessment of DILI that we must investigate in the future. It is critical to elucidate the mechanisms of drug metabolism and the pathophysiology of liver injury by various drugs to prevent DILI.
